Moxifloxacino Reiwa Healthcare

Moxifloxacin, the active ingredient in Moxifloxacino Reiwa Healthcare, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including pneumonia, sinusitis, skin‑structure infections and intra‑abdominal infections.

GNH USA supplies Moxifloxacino Reiwa Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in various organ systems. - Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms. - Complicated skin and skin‑structure infections: resolves deep tissue infection and promotes wound healing. - Intra‑abdominal infections: targets mixed aerobic and anaerobic bacteria to control intra‑abdominal sepsis.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Rash: skin redness or itching. - Elevated liver enzymes: mild hepatic enzyme increase.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or loss of function. - QT interval prolongation: risk of cardiac arrhythmia. - Severe allergic reactions: anaphylaxis, swelling, or breathing difficulty. - Clostridioides difficile infection: severe colitis. - Stevens‑Johnson syndrome: extensive skin blistering. - Hepatic failure: marked liver dysfunction.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Assess renal function: adjust therapy if renal impairment is present. - Monitor QT interval: avoid in patients with known prolonged QT or concurrent QT‑prolonging drugs. - Avoid in patients with tendon disorders: risk of tendon rupture is increased. - Use with caution in hepatic impairment: monitor liver enzymes regularly. - Review concomitant medications: identify potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): increased arrhythmia risk. - Antacids containing aluminum or magnesium: reduced absorption. - Warfarin: enhanced anticoagulant effect, monitor INR. - Systemic corticosteroids: heightened tendon rupture risk.

Moderate Interactions (Monitor Closely): - NSAIDs: potential for increased central nervous system effects. - Oral hypoglycemics: may alter blood glucose control. - Digoxin: possible increased serum levels. - Theophylline: risk of elevated theophylline concentrations. - Cyclosporine: may increase cyclosporine exposure.